Sildenafil Citrate Tablet, Film Coated
Product Images NDC 52817-295

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 52817-295). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Trupharma Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (20 mg Tablet Bottle Label)

Label for Sildenafil Tablets USP 20 mg, film-coated oral tablets distributed by TruPharma LLC and manufactured by Rubicon Research Private Limited, India. The label includes storage instructions, dosage reference, and a patient information website, with a quantity of 1,000 tablets and NDC 52817-295-00.*

FDA Label Image

Principal Display Panel (20 mg Tablet Bottle Label)

Label for Sildenafil Tablets, USP 20 mg, film-coated oral tablets, packaged in a container of 90 tablets. Distributed by TruPharma, LLC, Tampa, FL, and manufactured by Rubicon Research Private Limited, India. Includes storage instructions, dosage note, and barcode. The label shows the product NDC 52817-295-90 with patient information website and manufacturer details.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 06)

A step plot chart displaying estimated cumulative mortality rate (%) over time in years with three lines representing high dose, medium dose, and low dose groups. The vertical axis shows mortality rate percentages up to 25%, and the horizontal axis shows time from 0 to 5 years. The number of subjects at risk for each dose group is indicated above the chart at different time points.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 07)

A forest plot chart showing fold changes and 90% confidence intervals (CI) for drug interactions of sildenafil with various interacting drugs, measuring AUC and Cmax changes, and corresponding dosage recommendations such as no dose adjustment or coadministration not recommended.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 08)

A chart illustrating the fold change and 90% confidence interval of various interacting drugs on sildenafil's pharmacokinetics. The horizontal axis shows change relative to the interacting drug alone. The chart includes drugs like Acenocoumarol, Aspirin, Atorvastatin, Bosentan, various doses of Doxazosin, Ethinyloestradiol, Levonorgestrel, Phenprocoumon, Ritonavir, Saquinavir, and Tolbutamide. Recommendations such as 'No dose adjustment' or 'Coadministration not recommended' are indicated alongside each drug.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 09)

A line chart showing change from baseline in meters on the vertical axis over weeks of study (4, 8, 12) on the horizontal axis. The chart compares placebo with Sildenafil dosed at 20 mg TID, 40 mg TID, and 80 mg TID. Data points include error bars indicating variation at each time point for each group.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 10)

A forest plot illustrating the placebo-corrected change in 6-minute walk distance (meters) for Sildenafil 20 mg taken three times daily across various subgroups. The subgroups include baseline walk distance, etiology of pulmonary arterial hypertension (PAH), PH criteria for functional capacity and therapeutic class, gender, age, mean pulmonary artery pressure (PAP), and pulmonary vascular resistance index (PVRI). The plot shows point estimates with confidence intervals for each subgroup comparison between Sildenafil and placebo.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 11)

A Kaplan-Meier survival curve chart showing the percentage of subjects without a clinically worsening event over time (days from randomization). The chart compares two lines: solid for Placebo and dashed for Sildenafil, with Sildenafil showing a higher percentage of subjects without worsening over the study period.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 12)

A line plot showing the mean change from baseline in meters over a 12-week study period for three Sildenafil dosages: 1 mg TID, 5 mg TID, and 20 mg TID. Data points include standard error bars for each treatment at weeks 4, 8, and 12, illustrating efficacy progression over time.*

FDA Label Image

Structure Formula (Sildenafil Tablets Usp 20mg Structure)

Chemical structure of Sildenafil, the active ingredient in Sildenafil Citrate 20 mg film-coated tablets for oral use by TruPharma LLC. The structure shows molecular bonds featuring heterocyclic rings, an ethoxyphenyl group, and a methylated piperazine ring linked to a citrate moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.